Lv1
60 积分 2026-03-18 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
23天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
23天前
已完结
A0854 Real-world clinical outcomes of Avelumab (A), Pembrolizumab (P) or Enfortumab Vedotin (EV) in patients with metastatic Urothelial Carcinoma (mUC) with Squamous Differentiation (UCSD): Results from the Aron-2 study
1个月前
已关闭
A0876 Enfortumab vedotin-related skintoxicity as a predictor of survival among patients with advanced urothelial carcinoma: A systematic review and meta-analysis
1个月前
已关闭
A0861 Factors associated with inferior outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with first-line enfortumab vedotin plus pembrolizumab (1L EV+P): results from UNITE
1个月前
已关闭
皖公网安备34019202002308
